Notice: This company has been marked as potentially delisted and may not be actively trading. Landos Biopharma (LABP) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Global Asthma Treatment Market to Cross ~USD 32 Billion by 2030 | DelveInsightOctober 9, 2024 | uk.finance.yahoo.comLandos Biopharma (NASDAQ:LABP) Trading Up 0.6%Landos Biopharma (NASDAQ:LABP) Trading Up 0.6%May 24, 2024 | marketbeat.comAbbVie Completes Acquisition of Landos BiopharmaMay 23, 2024 | prnewswire.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPMay 11, 2024 | businesswire.comLABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024May 9, 2024 | investorplace.comEx-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit OutlookApril 26, 2024 | msn.comLandos Biopharma (LABP) Price Target Increased by 154.20% to 12.96April 17, 2024 | msn.comStockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVieApril 16, 2024 | prnewswire.comLandos Biopharma, Inc. (NASDAQ:LABP) Short Interest UpdateLandos Biopharma, Inc. (NASDAQ:LABP - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 4,900 shares, an increase of 345.5% from the March 15th total of 1,100 shares. Based on an average daily volume of 23,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.2% of the company's stock are short sold.April 10, 2024 | marketbeat.comLandos Biopharma, Inc. Expected to Earn Q1 2024 Earnings of ($0.88) Per Share (NASDAQ:LABP)Landos Biopharma, Inc. (NASDAQ:LABP - Free Report) - HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Landos Biopharma in a note issued to investors on Monday, April 1st. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share ofApril 3, 2024 | marketbeat.comHC Wainwright Reiterates Neutral Rating for Landos Biopharma (NASDAQ:LABP)HC Wainwright reiterated a "neutral" rating and set a $20.42 price target (down previously from $50.00) on shares of Landos Biopharma in a report on Monday.April 1, 2024 | marketbeat.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPMarch 27, 2024 | businesswire.comLandos Biopharma, Inc.: AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 27, 2024 | finanznachrichten.deLeerink Partners Remains a Hold on Landos Biopharma (LABP)March 27, 2024 | markets.businessinsider.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABPMarch 26, 2024 | prnewswire.comAbbVie To Acquire Landos Biopharma At $20.42/share In CashMarch 26, 2024 | markets.businessinsider.comAbbVie to buy Landos Biopharma for $137 millionMarch 26, 2024 | bizjournals.comWhy Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?March 26, 2024 | finance.yahoo.comWhy Is Landos Biopharma (LABP) Stock Up 168% Today?March 25, 2024 | investorplace.comShareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVieMarch 25, 2024 | prnewswire.comLABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to ShareholdersMarch 25, 2024 | businesswire.comAbbVie to buy Landos to expand pipeline of immunity-related illnessesMarch 25, 2024 | reuters.comAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 25, 2024 | prnewswire.comTrading was temporarily halted for "LABP" at 08:03 AM with a stated reason of "News pending."March 25, 2024 | marketbeat.comAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 25, 2024 | globenewswire.comLABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023March 21, 2024 | investorplace.comLandos Biopharma, Inc.: Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsMarch 21, 2024 | finanznachrichten.deRecap: Landos Biopharma Q4 EarningsMarch 21, 2024 | benzinga.comLandos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsMarch 21, 2024 | globenewswire.comXontogeny, LLC's Net WorthMarch 6, 2024 | benzinga.comWill Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?March 5, 2024 | finance.yahoo.comAmbrx Biopharma Stock (NASDAQ:AMAM) Dividends: History, Yield and DatesJanuary 10, 2024 | benzinga.comLandos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis OrganisationJanuary 8, 2024 | finance.yahoo.comLandos’s NX-13 shows symptom relief in Phase Ib ulcerative colitis trialNovember 22, 2023 | msn.comLandos Biopharma, Inc.: Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and ColitisNovember 21, 2023 | finanznachrichten.deLandos Biopharma Shares Rise 10% After Positive Trial Data for NX-13November 21, 2023 | marketwatch.comLandos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and ColitisNovember 21, 2023 | finance.yahoo.comLandos Biopharma GAAP EPS of -$0.94November 9, 2023 | msn.comLandos Biopharma: Q3 Earnings InsightsNovember 9, 2023 | benzinga.comLandos Biopharma Provides Company Update and Reports Third Quarter 2023 ResultsNovember 9, 2023 | finance.yahoo.comLandos Biopharma Provides Company Update and Reports Third Quarter 2023 ResultsNovember 9, 2023 | finance.yahoo.comTrading was temporarily halted for "LABP" at 09:11 AM with a stated reason of "LULD pause."November 1, 2023 | marketbeat.comLandos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific MeetingOctober 23, 2023 | finance.yahoo.comJonesTrading Sticks to Its Hold Rating for Landos Biopharma (LABP)September 22, 2023 | markets.businessinsider.comLandos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 CongressSeptember 19, 2023 | finance.yahoo.comLandos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 CongressSeptember 19, 2023 | finance.yahoo.comLandos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial CellsSeptember 14, 2023 | finance.yahoo.comLandos Biopharma, Inc.: Landos Biopharma Provides Business Update & Reports Second Quarter 2023 ResultsAugust 9, 2023 | finanznachrichten.deSCPS Scopus BioPharma Inc.August 9, 2023 | seekingalpha.comLandos Biopharma Provides Business Update & Reports Second Quarter 2023 ResultsAugust 9, 2023 | finance.yahoo.com Get Landos Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter. Email Address ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price. Click here for the ticker >>> LABP Media Mentions By Week LABP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LABP News Sentiment▼0.000.65▲Average Medical News Sentiment LABP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LABP Articles This Week▼00▲LABP Articles Average Week Get Landos Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rezolute News Atea Pharmaceuticals News Vanda Pharmaceuticals News Precigen News Lifecore Biomedical News Nature's Sunshine Products News AC Immune News Amylyx Pharmaceuticals News Procaps Group News COMPASS Pathways News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LABP) was last updated on 1/2/2025 by MarketBeat.com Staff From Our Partners3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredThe Next Big Thing in AI: Musk’s Secret SupplierWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredApple feeling the heat from NvidiaNvidia has moved on to the next frontier of AI it intends to dominate. And we believe the three companies p...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Landos Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Landos Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
